Posted by Michael Wonder on 07 Jan 2022
Dynacure receives fast track designation for DYN101, an investigational antisense oligonucleotide for the treatment of myotubular and centronuclear myopathies
6 January 2022 - Dynacure today announced that the U.S. FDA has granted fast track designation for its lead product candidate, DYN101.
DYN101 is currently being studied in UNITE-CNM, a multi-centre Phase 1/2 clinical trial for the two most common forms of myotubular and centronuclear myopathies, X-linked myotubular myopathy and autosomal dominant myotubular and centronuclear myopathies.
